Quantum Biopharma(QNTM)
$1.42-0.10 (-6.58%)
QNTM
Quantum Biopharma financials statements
$1.42
At close:-0.10 (-6.58%)
Want to see QNTM full AI Analyst Report?
Quantum Biopharma (QNTM) Ratios
704 Followers
Quantum Biopharma Ratios
QNTM's free cash flow for Q3 2026 was C$-2.75M. For the 2026 fiscal year, QNTM's free cash flow was increased by C$0.00 and operating cash flow was C$-2.75M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.07 | 1.80 | 2.43 | 2.28 | 5.28 |
| Quick Ratio | 1.06 | 1.79 | 2.43 | 2.28 | 5.28 |
| Cash Ratio | 0.31 | 0.90 | 0.60 | 2.17 | 4.05 |
| Solvency Ratio | -4.24 | -2.05 | -3.37 | -2.42 | -3.54 |
| Operating Cash Flow Ratio | -1.39 | -1.03 | -2.37 | -3.62 | -2.38 |
| Short-Term Operating Cash Flow Coverage | -4.48 | -8.92 | -36.02 | -94.27 | -69.03 |
| Net Current Asset Value | C$ 419.30K | C$ 5.37M | C$ 6.52M | C$ 9.98M | C$ 37.10M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.17 | 0.05 | 0.02 | 0.01 | 0.01 |
| Debt-to-Equity Ratio | 0.27 | 0.07 | 0.03 | 0.02 | 0.01 |
| Debt-to-Capital Ratio | 0.21 | 0.07 | 0.02 | 0.02 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.61 | 1.49 | 1.32 | 1.26 | 1.16 |
| Debt Service Coverage Ratio | -10.35 | -17.56 | -52.27 | -63.31 | -80.61 |
| Interest Coverage Ratio | -24.74 | -339.16 | -79563.54 | -561.83 | -486.19 |
| Debt to Market Cap | 0.08 | 0.18 | 0.01 | 0.01 | 0.01 |
| Interest Debt Per Share | 0.76 | 0.77 | 0.56 | 0.95 | 1.16 |
| Net Debt to EBITDA | 0.00 | 0.36 | 0.15 | 0.74 | 1.16 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 97.10% | 95.22% | 98.20% | 88.40% | 103.97% |
| EBT Per EBIT | 176.16% | 92.43% | 76.63% | 97.35% | 100.58% |
| Return on Assets (ROA) | -234.95% | -82.96% | -102.45% | -61.46% | -56.04% |
| Return on Equity (ROE) | -378.70% | -123.71% | -135.25% | -77.29% | -65.19% |
| Return on Capital Employed (ROCE) | -300.44% | -154.56% | -184.28% | -89.70% | -62.19% |
| Return on Invested Capital (ROIC) | -219.67% | -143.24% | -179.56% | -88.32% | -61.70% |
| Return on Tangible Assets | -394.47% | -116.56% | -147.72% | -89.52% | -75.46% |
| Earnings Yield | -109.12% | -339.46% | -49.15% | -77.35% | -98.99% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.55 | -6.05 | -17.78 | -47.55 | -38.59 |
| Free Cash Flow Per Share | -2.55 | -6.05 | -17.78 | -48.16 | -39.52 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | -77.85 | -41.49 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | -77.85 | -41.49 |
| Operating Cash Flow Coverage Ratio | -4.48 | -8.34 | -31.92 | -54.86 | -37.32 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -34.94% | -164.36% | -29.73% | -94.02% | -59.61% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.90 | -0.29 | -2.03 | -1.29 | -1.01 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.47 | 0.36 | 2.75 | 1.00 | 0.66 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.86 | -0.61 | -3.36 | -1.06 | -1.68 |
| Price-to-Operating Cash Flow Ratio | -2.86 | -0.61 | -3.36 | -1.08 | -1.72 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.01 | 0.08 | 0.03 | 0.02 |
| Enterprise Value Multiple | -0.93 | 0.07 | -2.16 | -0.64 | -0.03 |
| Enterprise Value | 23.96M | -987.08K | 34.00M | 14.06M | 940.33K |
| EV to EBITDA | -0.93 | 0.07 | -2.16 | -0.64 | -0.03 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.86 | 0.14 | -3.14 | -0.49 | -0.04 |
| EV to Operating Cash Flow | -2.86 | 0.14 | -3.14 | -0.50 | -0.05 |
| Tangible Book Value Per Share | 0.18 | 4.84 | 12.40 | 31.05 | 70.55 |
| Shareholders’ Equity Per Share | 2.10 | 10.10 | 21.73 | 51.26 | 100.69 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -7.97 | -12.49 | -29.39 | -39.62 | -65.63 |
| Tax Burden | 0.97 | 0.95 | 0.98 | 0.88 | 1.04 |
| Interest Burden | 1.02 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.32 | 0.46 | 0.59 | 1.06 | 0.61 |
Currency in CAD

